Literature DB >> 1314068

Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line.

S P Cole1, M J Pinkoski, G Bhardwaj, R G Deeley.   

Abstract

The doxorubicin-selected multidrug resistant small cell lung cancer cell line, H69AR, is cross-resistant to the Vinca alkaloids and epipodophyllotoxins, but does not overexpress P-glycoprotein, a 170 kDa plasma membrane efflux pump usually associated with this type of resistance. Monoclonal antibodies were raised against the H69AR cell line and one of these, MAb 3.186, recognises a peptide epitope on a 36 kDa phosphorylated protein that is membrane associated, but not presented on the external surface of H69AR cells (Mirski & Cole, 1991). In the present study, in vitro translation and molecular cloning techniques were used to determine the relative levels of mRNA corresponding to the 3.186 antigen. In addition, a cDNA clone containing an insert of approximately 1.4 kb was obtained by screening an H69AR cDNA library with 125I-MAb 3.186. Fragments of this cloned DNA hybridised to a single mRNA species of approximately 1.6 kb that was 5 to 6-fold elevated in H69AR cells. Partial DNA sequencing and restriction endonuclease mapping revealed identity of the cloned DNA with p36, a member of the annexin/lipocortin family of Ca2+ and phospholipid binding proteins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1314068      PMCID: PMC1977565          DOI: 10.1038/bjc.1992.103

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  46 in total

Review 1.  Lipocortins: an update.

Authors:  F Russo-Marie
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  1991-02       Impact factor: 4.006

Review 2.  Tyrosine protein kinase substrate p36: a member of the annexin family of Ca2+/phospholipid-binding proteins.

Authors:  V Gerke
Journal:  Cell Motil Cytoskeleton       Date:  1989

Review 3.  The biochemistry of P-glycoprotein-mediated multidrug resistance.

Authors:  J A Endicott; V Ling
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

4.  Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.

Authors:  S P Cole; E R Chanda; F P Dicke; J H Gerlach; S E Mirski
Journal:  Cancer Res       Date:  1991-07-01       Impact factor: 12.701

5.  Enhanced expression of the protein kinase substrate p36 in human hepatocellular carcinoma.

Authors:  M Frohlich; P Motté; K Galvin; H Takahashi; J Wands; M Ozturk
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

6.  Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line.

Authors:  S P Cole
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction.

Authors:  K E Noonan; C Beck; T A Holzmayer; J E Chin; J S Wunder; I L Andrulis; A F Gazdar; C L Willman; B Griffith; D D Von Hoff; I B Roninson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

8.  Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance.

Authors:  J H Gerlach; J A Endicott; P F Juranka; G Henderson; F Sarangi; K L Deuchars; V Ling
Journal:  Nature       Date:  1986 Dec 4-10       Impact factor: 49.962

9.  Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin.

Authors:  S E Mirski; J H Gerlach; S P Cole
Journal:  Cancer Res       Date:  1987-05-15       Impact factor: 12.701

10.  Effect of duration of exposure to verapamil on vincristine activity against multidrug-resistant human leukemic cell lines.

Authors:  C E Cass; A Janowska-Wieczorek; M A Lynch; H Sheinin; A A Hindenburg; W T Beck
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

View more
  25 in total

1.  Specific down-regulation of annexin II expression in human cells interferes with cell proliferation.

Authors:  Y Chiang; A Rizzino; Z A Sibenaller; M S Wold; J K Vishwanatha
Journal:  Mol Cell Biochem       Date:  1999-09       Impact factor: 3.396

2.  Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties.

Authors:  M J Page; B Amess; R R Townsend; R Parekh; A Herath; L Brusten; M J Zvelebil; R C Stein; M D Waterfield; S C Davies; M J O'Hare
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

3.  Quantitative proteomic analysis identifying three annexins as lymph node metastasis-related proteins in lung adenocarcinoma.

Authors:  Ying-Fu Liu; Yong-Heng Chen; Mao-Yu Li; Peng-Fei Zhang; Fang Peng; Guo-Qing Li; Zhi-Qiang Xiao; Zhu-Chu Chen
Journal:  Med Oncol       Date:  2010-12-04       Impact factor: 3.064

Review 4.  Cellular models for multiple drug resistance in cancer.

Authors:  M Clynes
Journal:  In Vitro Cell Dev Biol       Date:  1993-03

Review 5.  Role of Annexin-II in GI cancers: interaction with gastrins/progastrins.

Authors:  Pomila Singh
Journal:  Cancer Lett       Date:  2006-12-22       Impact factor: 8.679

6.  Homing of cancer cells to the bone.

Authors:  Anjali Mishra; Yusuke Shiozawa; Kenneth J Pienta; Russell S Taichman
Journal:  Cancer Microenviron       Date:  2011-08-09

7.  Prognostic significance of annexin II expression in non-small cell lung cancer.

Authors:  C-H Luo; Q-Q Liu; P-F Zhang; M-Y Li; Z-C Chen; Y-F Liu
Journal:  Clin Transl Oncol       Date:  2013-03-26       Impact factor: 3.405

Review 8.  Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment.

Authors:  Jian-Ting Zhang; Yang Liu
Journal:  Cancer Treat Rev       Date:  2007-09-12       Impact factor: 12.111

Review 9.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

10.  Annexin II represents metastatic potential in clear-cell renal cell carcinoma.

Authors:  Y Ohno; M Izumi; T Kawamura; T Nishimura; K Mukai; M Tachibana
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.